Marker Therapeutics Inc (MRKR)

[pharmeng]

I agree, very positive. The fact that they are splitting trial cost is a help as well. Many of these PD-1 combo studies make the smaller the company pay.

They're also looking for CR and PFS at 6 mo for the end points, so hopefully we can get some interim data by year's end. I think one thing that has been holding this back, is no true efficacy data yet, just immune response. Will be great once we get some prelim results.